Accelerated Approvals Could Be Improved By Focusing On Benefit/Risk, Making Withdrawal Easier

 
• By Sue Sutter

Applying the expedited pathway in the context of a preliminary benefit/risk assessment, rather than focusing solely on predictive surrogate or intermediate clinical endpoints, would give the US FDA more flexibility, Friends of Cancer Research working group says in a new white paper.

the waiter cleaning the table in a outdoor cafe. He collects dirty dishes in a tray.
Giving US FDA the ability to easily clear the table of an accelerated approval drug that fails to confirm clinical benefit is proposed in a new white paper. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards